Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1753 studies found for:    docetaxel
Show Display Options
Rank Status Study
1 Completed Study of Usefulness of Genotyping to Predict Docetaxel Exposure and Adverse Events
Conditions: CYP3A Phenotyping;   CYP3A5 and MDR1 Genotyping;   Docetaxel Toxicity;   Associations Between Genetic Data and Docetaxel Toxicity
Intervention: Drug: docetaxel + CEF
2 Completed
Has Results
Randomized Study of Docetaxel +/- ZD6474 in Metastatic TCC
Conditions: Transitional Cell Carcinoma;   Bladder Cancer
Interventions: Drug: Docetaxel;   Drug: Zactima;   Drug: Placebo
3 Completed Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer
Condition: Advanced Solid Cancers
Intervention: Drug: CKD-810, Taxotere inj.
4 Unknown  Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer
Condition: Hormone Refractory Prostate Cancer
Interventions: Drug: Docetaxel * Sunitinib;   Drug: Docetaxel
5 Completed The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer
Conditions: Nausea and Vomiting, Chemotherapy-Induced;   Cancer
Interventions: Drug: Docetaxel;   Drug: Casopitant/Docetaxel
6 Recruiting Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients
Condition: Breast Cancer
Interventions: Drug: Taxotere;   Drug: Adriamycin/Cytoxan;   Drug: docetaxol;   Drug: doxorubicin
7 Suspended A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: Docetaxel, PSK®;   Drug: Docetaxel, Placebo
8 Terminated
Has Results
Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: PR104;   Drug: docetaxel;   Drug: Granulocyte colony-stimulating factor
9 Recruiting Docetaxel and Lycopene in Metastatic Prostate Cancer
Condition: Adenocarcinoma of the Prostate
Intervention: Drug: Lycopene and Docetaxel
10 Terminated RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Docetaxel;   Drug: RAD001;   Drug: Dexamethasone
11 Terminated Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
Conditions: Breast Cancer;   Lung Cancer;   Pulmonary Cancer;   Non-Small-Cell Lung Carcinoma;   Prostate Cancer;   Prostatic Cancer;   Gastric Cancer;   Stomach Cancer
Intervention: Drug: MGCD0103 & Docetaxel
12 Withdrawn Phase II: RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Docetaxel;   Drug: RAD001;   Drug: Dexamethasone
13 Completed
Has Results
A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors
Condition: Malignant Solid Tumor
Interventions: Biological: Ramucirumab;   Drug: Docetaxel
14 Completed Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers
Condition: Metastatic Breast Cancer
Interventions: Drug: Capecitabine;   Drug: Docetaxel
15 Not yet recruiting Pharmacokinetic Study of Docetaxel-PNP and Taxotere to Treat Patient With Advanced Solid Cancer
Condition: Solid Tumor
Interventions: Drug: Docetaxel-PNP;   Drug: Taxotere
16 Completed Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
Condition: Cancer
Interventions: Drug: docetaxel;   Drug: NPI-2358 + docetaxel
17 Completed
Has Results
Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC)
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Docetaxel and Cisplatin
18 Not yet recruiting Induction Study of Cisplatin, Docetaxel, and Nintedanib Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC)
Condition: Lung Cancer
Interventions: Drug: Nintedanib;   Drug: Cisplatin;   Drug: Docetaxel
19 Completed
Has Results
Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive
Condition: Breast Cancer
Interventions: Drug: Herceptin;   Drug: Sunitinib;   Drug: Taxotere
20 Completed
Has Results
Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
Condition: Metastatic Prostate Cancer
Interventions: Drug: Dasatinib;   Drug: Docetaxel

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years